Kushida Clete A, Chediak Alejandro, Berry Richard B, Brown Lee K, Gozal David, Iber Conrad, Parthasarathy Sairam, Quan Stuart F, Rowley James A
Stanford University Center of Excellence for Sleep Disorders, 401 Quarry Road, Suite 3301, Stanford, CA 94305-5730, USA.
J Clin Sleep Med. 2008 Apr 15;4(2):157-71.
Positive airway pressure (PAP) devices are used to treat patients with sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA). After a patient is diagnosed with OSA, the current standard of practice involves performing attended polysomnography (PSG), during which positive airway pressure is adjusted throughout the recording period to determine the optimal pressure for maintaining upper airway patency. Continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BPAP) represent the two forms of PAP that are manually titrated during PSG to determine the single fixed pressure of CPAP or the fixed inspiratory and expiratory positive airway pressures (IPAP and EPAP, respectively) of BPAP for subsequent nightly usage. A PAP Titration Task Force of the American Academy of Sleep Medicine reviewed the available literature. Based on this review, the Task Force developed these recommendations for conducting CPAP and BPAP titrations. Major recommendations are as follows: (1) All potential PAP titration candidates should receive adequate PAP education, hands-on demonstration, careful mask fitting, and acclimatization prior to titration. (2) CPAP (IPAP and/or EPAP for patients on BPAP) should be increased until the following obstructive respiratory events are eliminated (no specific order) or the recommended maximum CPAP (IPAP for patients on BPAP) is reached: apneas, hypopneas, respiratory effort-related arousals (RERAs), and snoring. (3) The recommended minimum starting CPAP should be 4 cm H2O for pediatric and adult patients, and the recommended minimum starting IPAP and EPAP should be 8 cm H2O and 4 cm H2O, respectively, for pediatric and adult patients on BPAP. (4) The recommended maximum CPAP should be 15 cm H2O (or recommended maximum IPAP of 20 cm H2O if on BPAP) for patients < 12 years, and 20 cm H2O (or recommended maximum IPAP of 30 cm H2O if on BPAP) for patients > or = 12 years. (5) The recommended minimum IPAP-EPAP differential is 4 cm H2O and the recommended maximum IPAP-EPAP differential is 10 cm H2O (6) CPAP (IPAP and/or EPAP for patients on BPAP depending on the type of event) should be increased by at least 1 cm H2O with an interval no shorter than 5 min, with the goal of eliminating obstructive respiratory events. (7) CPAP (IPAP and EPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 1 obstructive apnea is observed for patients < 12 years, or if at least 2 obstructive apneas are observed for patients > or = 12 years. (8) CPAP (IPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 1 hypopnea is observed for patients < 12 years, or if at least 3 hypopneas are observed for patients > or = 12 years. (9) CPAP (IPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 3 RERAs are observed for patients < 12 years, or if at least 5 RERAs are observed for patients > or = 12 years. (10) CPAP (IPAP for patients on BPAP) may be increased from any CPAP (or IPAP) level if at least 1 min of loud or unambiguous snoring is observed for patients < 12 years, or if at least 3 min of loud or unambiguous snoring are observed for patients > or = 12 years. (11) The titration algorithm for split-night CPAP or BPAP titration studies should be identical to that of full-night CPAP or BPAP titration studies, respectively. (12) If the patient is uncomfortable or intolerant of high pressures on CPAP, the patient may be tried on BPAP. If there are continued obstructive respiratory events at 15 cm H2O of CPAP during the titration study, the patient may be switched to BPAP. (13) The pressure of CPAP or BPAP selected for patient use following the titration study should reflect control of the patient's obstructive respiration by a low (preferably < 5 per hour) respiratory disturbance index (RDI) at the selected pressure, a minimum sea level SpO2 above 90% at the pressure, and with a leak within acceptable parameters at the pressure.) (14) An optimal titration reduces RDI < 5 for at least a 15-min duration and should include supine REM sleep at the selected pressure that is not continually interrupted by spontaneous arousals or awakenings. (15) A good titration reduces RDI < or = 10 or by 50% if the baseline RDI < 15 and should include supine REM sleep that is not continually interrupted by spontaneous arousals or awakenings at the selected pressure. (16) An adequate titration does not reduce the RDI < or = 10 but reduces the RDI by 75% from baseline (especially in severe OSA patients), or one in which the titration grading criteria for optimal or good are met with the exception that supine REM sleep did not occur at the selected pressure. (17) An unacceptable titration is one that does not meet any one of the above grades. (18) A repeat PAP titration study should be considered if the initial titration does not achieve a grade of optimal or good and, if it is a split-night PSG study, it fails to meet AASM criteria (i.e., titration duration should be > 3 hr).
气道正压通气(PAP)设备用于治疗患有睡眠相关呼吸障碍(SRBD)的患者,包括阻塞性睡眠呼吸暂停(OSA)。患者被诊断为OSA后,目前的标准治疗方法包括进行有医护人员在场的多导睡眠图(PSG)检查,在此期间,在整个记录期内调整气道正压,以确定维持上气道通畅的最佳压力。持续气道正压通气(CPAP)和双水平气道正压通气(BPAP)是PAP的两种形式,在PSG检查期间进行手动滴定,以确定CPAP的单一固定压力或BPAP的固定吸气和呼气气道正压(分别为IPAP和EPAP),以供后续每晚使用。美国睡眠医学学会的一个PAP滴定工作组回顾了现有文献。基于此回顾,工作组制定了这些进行CPAP和BPAP滴定的建议。主要建议如下:(1)所有可能进行PAP滴定的候选人在滴定前应接受充分的PAP教育、实际操作演示、仔细的面罩适配和适应过程。(2)应增加CPAP(BPAP患者的IPAP和/或EPAP),直到以下阻塞性呼吸事件被消除(无特定顺序)或达到推荐的最大CPAP(BPAP患者的IPAP):呼吸暂停、呼吸浅慢、呼吸努力相关觉醒(RERA)和打鼾。(3)对于儿童和成人患者,推荐的最低起始CPAP应为4 cm H2O,对于使用BPAP的儿童和成人患者,推荐的最低起始IPAP和EPAP分别应为8 cm H2O和4 cm H2O。(4)对于<12岁的患者,推荐的最大CPAP应为15 cm H2O(如果使用BPAP,则推荐的最大IPAP为20 cm H2O),对于≥12岁的患者,推荐的最大CPAP应为20 cm H2O(如果使用BPAP,则推荐的最大IPAP为30 cm H2O)。(5)推荐的最低IPAP-EPAP差值为4 cm H2O,推荐的最大IPAP-EPAP差值为10 cm H2O。(6)CPAP(根据事件类型,BPAP患者的IPAP和/或EPAP)应至少增加1 cm H2O,间隔不短于5分钟,目标是消除阻塞性呼吸事件。(7)如果<12岁的患者观察到至少1次阻塞性呼吸暂停,或≥12岁的患者观察到至少2次阻塞性呼吸暂停,则应从任何CPAP(或IPAP)水平增加CPAP(BPAP患者的IPAP和EPAP)。(8)如果<12岁的患者观察到至少1次呼吸浅慢,或≥12岁的患者观察到至少3次呼吸浅慢,则应从任何CPAP(或IPAP)水平增加CPAP(BPAP患者的IPAP)。(9)如果<12岁的患者观察到至少3次RERA,或≥12岁的患者观察到至少5次RERA,则应从任何CPAP(或IPAP)水平增加CPAP(BPAP患者的IPAP)。(10)如果<12岁的患者观察到至少1分钟的大声或明确打鼾,或≥12岁的患者观察到至少3分钟的大声或明确打鼾,则CPAP(BPAP患者的IPAP)可从任何CPAP(或IPAP)水平增加。(11)分夜CPAP或BPAP滴定研究的滴定算法应分别与全夜CPAP或BPAP滴定研究的算法相同。(12)如果患者对CPAP的高压感到不适或不耐受,可以尝试让患者使用BPAP。如果在滴定研究期间CPAP为15 cm H2O时仍有持续的阻塞性呼吸事件,患者可以改用BPAP。(13)滴定研究后为患者选择的CPAP或BPAP压力应反映在所选择的压力下通过低(最好<每小时5次)呼吸紊乱指数(RDI)对患者阻塞性呼吸的控制,在该压力下海平面最低SpO2高于90%,并且在该压力下泄漏在可接受的参数范围内。(14)最佳滴定应使RDI在至少15分钟内<5,并且应包括在所选压力下的仰卧快速眼动睡眠,该睡眠不会持续被自发觉醒或唤醒打断。(15)良好的滴定应使RDI<或=10,或者如果基线RDI<15,则使RDI降低50%,并且应包括在所选压力下的仰卧快速眼动睡眠,该睡眠不会持续被自发觉醒或唤醒打断。(16)充分的滴定不会使RDI<或=10,但会使RDI从基线降低75%(特别是在重度OSA患者中),或者是一种滴定符合最佳或良好的分级标准,但在所选压力下未出现仰卧快速眼动睡眠的情况。(17)不可接受滴度是指不符合上述任何一个等级的滴度。(18)如果初始滴定未达到最佳或良好等级,或者如果是分夜PSG研究但未达到美国睡眠医学学会标准(即滴定持续时间应>3小时),则应考虑重复PAP滴定研究。